Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy

the Korean multicenter retrospective study

Jinseok Kim, Dok Hyun Yoon, Seonyang Park, Sung Soo Yoon, Seok Goo Cho, Chang Ki Min, Je Jung Lee, Deok Hwan Yang, Jae Yong Kwak, Hyeon Seok Eom, Won Seog Kim, Hawk Kim, Young Rok Do, Joon Ho Moon, Jihye Lee, Cheolwon Suh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Plerixafor in combination with granulocyte colony-stimulating factor (G-CSF) has been shown to improve the rates of successful peripheral blood stem cell (PBSC) mobilization in patients with malignant lymphoma or multiple myeloma (MM) who experienced prior failure of PBSC mobilization. We evaluated the mobilization results of re-mobilization using plerixafor and G-CSF in insufficiently mobilizing patients. Forty-four patients with lymphoma (n = 29) or MM (n = 15) were included in the study. The median age was 50 (range, 24–64) years. Previous mobilization regimens were chemotherapy with G-CSF (n = 28), including cyclophosphamide with G-CSF (n = 15), and G-CSF only (n = 16). All patients with lymphoma achieved at least partial response (PR) before the mobilization, including 13 complete responses (CRs). Eleven patients with MM achieved at least PR and four patients with MM were in stable disease before mobilization. The median number of apheresis was 3 (range, 1–6). The median yield of PBSC collections was 3.41 (0.13–38.11) × 106 CD34+ cells/kg. Thirty-four (77.3 %) patients had successful collections defined as at least 2 × 106 CD34+ cells/kg. The rate of successful collections was not different between the two underlying diseases (79.3 % in lymphoma and 73.3 % in MM). Of the entire cohort, 38 (86.4 %) of patients went on to receive an autologous transplant. Previous long-term use of high-risk drugs (>4 cycles use of alkylating agents, platinum-containing agents, or thalidomide) (HR 10.8, 95 % CI 1.1–110.0, P = 0.043) and low platelet count (<100 × 109/L) 1 day before the first apheresis (HR 27.9, 95 % CI 2.9–273.7, P = 0.004) were independent prognostic factors for predicting failure of PBSC re-mobilization using plerixafor and G-CSF. In conclusion, re-mobilization using plerixafor and G-CSF showed a success rate of 77.3 % in patients with lymphoma or MM who experienced prior failure of PBSC mobilization, and the majority of them underwent autologous transplant. Therefore, plerixafor-based re-mobilization was an effective method in poor mobilizers.

Original languageEnglish
Pages (from-to)603-611
Number of pages9
JournalAnnals of Hematology
Volume95
Issue number4
DOIs
Publication statusPublished - 2016 Mar 1

Fingerprint

Granulocyte Colony-Stimulating Factor
Multiple Myeloma
Multicenter Studies
Lymphoma
Retrospective Studies
Drug Therapy
Hematopoietic Stem Cell Mobilization
Blood Component Removal
Autografts
JM 3100
Thalidomide
Alkylating Agents
Platinum
Platelet Count
Cyclophosphamide
Peripheral Blood Stem Cells

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Kim, Jinseok ; Yoon, Dok Hyun ; Park, Seonyang ; Yoon, Sung Soo ; Cho, Seok Goo ; Min, Chang Ki ; Lee, Je Jung ; Yang, Deok Hwan ; Kwak, Jae Yong ; Eom, Hyeon Seok ; Kim, Won Seog ; Kim, Hawk ; Do, Young Rok ; Moon, Joon Ho ; Lee, Jihye ; Suh, Cheolwon. / Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy : the Korean multicenter retrospective study. In: Annals of Hematology. 2016 ; Vol. 95, No. 4. pp. 603-611.
@article{793d028c962542ff8326bea3109165c5,
title = "Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study",
abstract = "Plerixafor in combination with granulocyte colony-stimulating factor (G-CSF) has been shown to improve the rates of successful peripheral blood stem cell (PBSC) mobilization in patients with malignant lymphoma or multiple myeloma (MM) who experienced prior failure of PBSC mobilization. We evaluated the mobilization results of re-mobilization using plerixafor and G-CSF in insufficiently mobilizing patients. Forty-four patients with lymphoma (n = 29) or MM (n = 15) were included in the study. The median age was 50 (range, 24–64) years. Previous mobilization regimens were chemotherapy with G-CSF (n = 28), including cyclophosphamide with G-CSF (n = 15), and G-CSF only (n = 16). All patients with lymphoma achieved at least partial response (PR) before the mobilization, including 13 complete responses (CRs). Eleven patients with MM achieved at least PR and four patients with MM were in stable disease before mobilization. The median number of apheresis was 3 (range, 1–6). The median yield of PBSC collections was 3.41 (0.13–38.11) × 106 CD34+ cells/kg. Thirty-four (77.3 {\%}) patients had successful collections defined as at least 2 × 106 CD34+ cells/kg. The rate of successful collections was not different between the two underlying diseases (79.3 {\%} in lymphoma and 73.3 {\%} in MM). Of the entire cohort, 38 (86.4 {\%}) of patients went on to receive an autologous transplant. Previous long-term use of high-risk drugs (>4 cycles use of alkylating agents, platinum-containing agents, or thalidomide) (HR 10.8, 95 {\%} CI 1.1–110.0, P = 0.043) and low platelet count (<100 × 109/L) 1 day before the first apheresis (HR 27.9, 95 {\%} CI 2.9–273.7, P = 0.004) were independent prognostic factors for predicting failure of PBSC re-mobilization using plerixafor and G-CSF. In conclusion, re-mobilization using plerixafor and G-CSF showed a success rate of 77.3 {\%} in patients with lymphoma or MM who experienced prior failure of PBSC mobilization, and the majority of them underwent autologous transplant. Therefore, plerixafor-based re-mobilization was an effective method in poor mobilizers.",
author = "Jinseok Kim and Yoon, {Dok Hyun} and Seonyang Park and Yoon, {Sung Soo} and Cho, {Seok Goo} and Min, {Chang Ki} and Lee, {Je Jung} and Yang, {Deok Hwan} and Kwak, {Jae Yong} and Eom, {Hyeon Seok} and Kim, {Won Seog} and Hawk Kim and Do, {Young Rok} and Moon, {Joon Ho} and Jihye Lee and Cheolwon Suh",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s00277-016-2589-y",
language = "English",
volume = "95",
pages = "603--611",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "4",

}

Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy : the Korean multicenter retrospective study. / Kim, Jinseok; Yoon, Dok Hyun; Park, Seonyang; Yoon, Sung Soo; Cho, Seok Goo; Min, Chang Ki; Lee, Je Jung; Yang, Deok Hwan; Kwak, Jae Yong; Eom, Hyeon Seok; Kim, Won Seog; Kim, Hawk; Do, Young Rok; Moon, Joon Ho; Lee, Jihye; Suh, Cheolwon.

In: Annals of Hematology, Vol. 95, No. 4, 01.03.2016, p. 603-611.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy

T2 - the Korean multicenter retrospective study

AU - Kim, Jinseok

AU - Yoon, Dok Hyun

AU - Park, Seonyang

AU - Yoon, Sung Soo

AU - Cho, Seok Goo

AU - Min, Chang Ki

AU - Lee, Je Jung

AU - Yang, Deok Hwan

AU - Kwak, Jae Yong

AU - Eom, Hyeon Seok

AU - Kim, Won Seog

AU - Kim, Hawk

AU - Do, Young Rok

AU - Moon, Joon Ho

AU - Lee, Jihye

AU - Suh, Cheolwon

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Plerixafor in combination with granulocyte colony-stimulating factor (G-CSF) has been shown to improve the rates of successful peripheral blood stem cell (PBSC) mobilization in patients with malignant lymphoma or multiple myeloma (MM) who experienced prior failure of PBSC mobilization. We evaluated the mobilization results of re-mobilization using plerixafor and G-CSF in insufficiently mobilizing patients. Forty-four patients with lymphoma (n = 29) or MM (n = 15) were included in the study. The median age was 50 (range, 24–64) years. Previous mobilization regimens were chemotherapy with G-CSF (n = 28), including cyclophosphamide with G-CSF (n = 15), and G-CSF only (n = 16). All patients with lymphoma achieved at least partial response (PR) before the mobilization, including 13 complete responses (CRs). Eleven patients with MM achieved at least PR and four patients with MM were in stable disease before mobilization. The median number of apheresis was 3 (range, 1–6). The median yield of PBSC collections was 3.41 (0.13–38.11) × 106 CD34+ cells/kg. Thirty-four (77.3 %) patients had successful collections defined as at least 2 × 106 CD34+ cells/kg. The rate of successful collections was not different between the two underlying diseases (79.3 % in lymphoma and 73.3 % in MM). Of the entire cohort, 38 (86.4 %) of patients went on to receive an autologous transplant. Previous long-term use of high-risk drugs (>4 cycles use of alkylating agents, platinum-containing agents, or thalidomide) (HR 10.8, 95 % CI 1.1–110.0, P = 0.043) and low platelet count (<100 × 109/L) 1 day before the first apheresis (HR 27.9, 95 % CI 2.9–273.7, P = 0.004) were independent prognostic factors for predicting failure of PBSC re-mobilization using plerixafor and G-CSF. In conclusion, re-mobilization using plerixafor and G-CSF showed a success rate of 77.3 % in patients with lymphoma or MM who experienced prior failure of PBSC mobilization, and the majority of them underwent autologous transplant. Therefore, plerixafor-based re-mobilization was an effective method in poor mobilizers.

AB - Plerixafor in combination with granulocyte colony-stimulating factor (G-CSF) has been shown to improve the rates of successful peripheral blood stem cell (PBSC) mobilization in patients with malignant lymphoma or multiple myeloma (MM) who experienced prior failure of PBSC mobilization. We evaluated the mobilization results of re-mobilization using plerixafor and G-CSF in insufficiently mobilizing patients. Forty-four patients with lymphoma (n = 29) or MM (n = 15) were included in the study. The median age was 50 (range, 24–64) years. Previous mobilization regimens were chemotherapy with G-CSF (n = 28), including cyclophosphamide with G-CSF (n = 15), and G-CSF only (n = 16). All patients with lymphoma achieved at least partial response (PR) before the mobilization, including 13 complete responses (CRs). Eleven patients with MM achieved at least PR and four patients with MM were in stable disease before mobilization. The median number of apheresis was 3 (range, 1–6). The median yield of PBSC collections was 3.41 (0.13–38.11) × 106 CD34+ cells/kg. Thirty-four (77.3 %) patients had successful collections defined as at least 2 × 106 CD34+ cells/kg. The rate of successful collections was not different between the two underlying diseases (79.3 % in lymphoma and 73.3 % in MM). Of the entire cohort, 38 (86.4 %) of patients went on to receive an autologous transplant. Previous long-term use of high-risk drugs (>4 cycles use of alkylating agents, platinum-containing agents, or thalidomide) (HR 10.8, 95 % CI 1.1–110.0, P = 0.043) and low platelet count (<100 × 109/L) 1 day before the first apheresis (HR 27.9, 95 % CI 2.9–273.7, P = 0.004) were independent prognostic factors for predicting failure of PBSC re-mobilization using plerixafor and G-CSF. In conclusion, re-mobilization using plerixafor and G-CSF showed a success rate of 77.3 % in patients with lymphoma or MM who experienced prior failure of PBSC mobilization, and the majority of them underwent autologous transplant. Therefore, plerixafor-based re-mobilization was an effective method in poor mobilizers.

UR - http://www.scopus.com/inward/record.url?scp=84959573566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959573566&partnerID=8YFLogxK

U2 - 10.1007/s00277-016-2589-y

DO - 10.1007/s00277-016-2589-y

M3 - Article

VL - 95

SP - 603

EP - 611

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 4

ER -